Combination therapy of sorafenib and drug-eluting bead transarterial chemoembolization for advanced hepatocellular carcinoma with and without hepatic arteriovenous shunt
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Chinese Medical Association"
DOI: 10.1097/jcma.0000000000000696
Abstract: Background: To compare the efficacy and safety of combination therapy with sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in advanced hepatocellular carcinoma (HCC) with or without hepatic arteriovenous shunt (HAVS). Methods: This retrospective, single-center study… read more here.
Keywords: tace; combination; therapy sorafenib; combination therapy ... See more keywords
Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-22-397
Abstract: Background Regorafenib is a standard 2nd-line treatment for patients with advanced hepatocellular carcinoma (HCC), but the efficacy and safety of sequential therapy with sorafenib and regorafenib among advanced HCC patients in China is not clear.… read more here.
Keywords: sequential therapy; sorafenib; therapy sorafenib; treatment ... See more keywords